Gross inspection of tumors at the terminal time point (day 32) (Fig. 6a, lower panel) and measurement of tumor mass (Fig. 6b) demonstrated that control mice had substantially larger tumor burden that broke free of the subrenal capsule to appose the abdominal wall, while mice treated with anti-CAIX mAbs had tumors that remained attached to the kidney parenchyma. This evidence concerns the gene CA9 and neoplasm.